Citius pharmaceuticals, inc. reports fiscal first quarter 2023 financial results and provides business update

$36.9 million in cash and cash equivalents as of december 31, 2022; runway through february 2024 uptick in patient recruitment for mino-lok® phase 3 trial halo-lido phase 2b trial nearing completion cranford, n.j. , feb. 10, 2023 /prnewswire/ -- citius pharmaceuticals, inc. ("citius" or the "company") (nasdaq: ctxr), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal first quarter ended december 31, 2022.
CTXR Ratings Summary
CTXR Quant Ranking